Insights into New-onset Arthritis in Patients with Hidradenitis Suppurativa
DOI:
https://doi.org/10.2340/actadv.v104.40145Keywords:
hidradenitis suppurativa, arthritis, adalimumabAbstract
Abstract is missing (Short communication)
Downloads
References
Aletaha D, Epstein AJ, Skup M, Zueger P, Garg V, Panaccione R. Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study. Adv Ther 2019; 36: 1672-1683.
https://doi.org/10.1007/s12325-019-00964-z DOI: https://doi.org/10.1007/s12325-019-00964-z
Martorell A, Jfri A, Koster SBL, Gomez-Palencia P, Solera M, Alfaro-Rubio A, et al. Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol 2020; 34: 1309-1318.
https://doi.org/10.1111/jdv.16183 DOI: https://doi.org/10.1111/jdv.16183
Hanna N, Silverberg OM, Reaume M, Gladman D, Davis MDP, Piguet V, et al. Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis. Int J Dermatol 2022; 61: 1069-1079.
https://doi.org/10.1111/ijd.15860 DOI: https://doi.org/10.1111/ijd.15860
Almuhanna N, Finstad A, Alhusayen R. Association between hidradenitis suppurativa and inflammatory arthritis: a - review and meta-analysis. Dermatology 2021; 237: 740-747.
https://doi.org/10.1159/000514582 DOI: https://doi.org/10.1159/000514582
Schneeweiss MC, Kim SC, Schneeweiss S, Rosmarin D, Merola JF. Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa. JAMA Dermatol 2020; 156: 342-345.
https://doi.org/10.1001/jamadermatol.2019.4590 DOI: https://doi.org/10.1001/jamadermatol.2019.4590
Haddad EB, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb) 2022; 12: 1501-1533.
https://doi.org/10.1007/s13555-022-00737-7 DOI: https://doi.org/10.1007/s13555-022-00737-7
Felice C, Dal Buono A, Gabbiadini R, Rattazzi M, Armuzzi A. Cytokines in spondyloarthritis and inflammatory bowel diseases: from pathogenesis to therapeutic implications. Int J Mol Sci 2023; 24: 3957.
https://doi.org/10.3390/ijms24043957 DOI: https://doi.org/10.3390/ijms24043957
Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018; 53: 49-63.
https://doi.org/10.1159/000479475 DOI: https://doi.org/10.1159/000479475
Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. Dermatology 2020; 236: 307-313.
https://doi.org/10.1159/000506074 DOI: https://doi.org/10.1159/000506074
Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol 2017; 76: 334-341.
https://doi.org/10.1016/j.jaad.2016.08.012 DOI: https://doi.org/10.1016/j.jaad.2016.08.012
Garcovich S, De Simone C, Genovese G, Berti E, Cugno M, Marzano AV. Paradoxical skin reactions to biologics in patients with rheumatologic disorders. Front Pharmacol 2019; 10: 282.
https://doi.org/10.3389/fphar.2019.00282 DOI: https://doi.org/10.3389/fphar.2019.00282
Alivernini S, Pugliese D, Tolusso B, Bui L, Petricca L, Guidi L, et al. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open 2018; 4: e000667.
https://doi.org/10.1136/rmdopen-2018-000667 DOI: https://doi.org/10.1136/rmdopen-2018-000667
Ward D, Nyboe Andersen N, Gørtz S, Thorn Iversen A, Højgaard Allin K, Beaugerie L, et al. Tumor necrosis factor inhibitors in inflammatory bowel disease and risk of immune mediated inflammatory diseases. Clin Gastroenterol Hepatol 2024; 22: 135-143.e8.
https://doi.org/10.1016/j.cgh.2023.06.025 DOI: https://doi.org/10.1016/j.cgh.2023.06.025
Megna M, Ocampo-Garza SS, Potestio L, Fontanella G, Gallo L, Cacciapuoti S, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines 2021; 9: 1482.
https://doi.org/10.3390/biomedicines9101482 DOI: https://doi.org/10.3390/biomedicines9101482
Garcia-Melendo C, Vilarrasa E, Cubiró X, Bittencourt F, Puig L. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. Dermatol Ther 2020; 33: e14180.
https://doi.org/10.1111/dth.14180 DOI: https://doi.org/10.1111/dth.14180
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Patricia Garbayo-Salmons, Mireia Moreno Martínez-Losa, Vicente Exposito-Serrano, Miquel Ribera, Joan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
